For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Intellia Therapeutics, Inc.

USPTO Granted Patents = 15

EPO Patents = 2

Trademarks = 8

Forward Citations = 10

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Walter R Strapps (6 out of 19 patents)

Shobu Odate (5 out of 5 patents)

Reynald Michael Lescarbeau (5 out of 5 patents)

4. Yi Yang (3 out of 4 patents)

5. Amy Madison Rhoden Smith (3 out of 3 patents)

6. Christian Dombrowski (3 out of 3 patents)

7. Jessica Lynn Seitzer (3 out of 3 patents)

8. Morag Helen Stewart (2 out of 9 patents)

9. David Morrissey (2 out of 7 patents)

10. Craig Stephen Mickanin (2 out of 3 patents)

11. Arti Mahendra Prakash Kanjolia (2 out of 2 patents)

12. Jonathan Douglas Finn (2 out of 2 patents)

13. Jennifer Brogdon (1 out of 37 patents)

14. Christos Kyratsous (1 out of 34 patents)

15. Celeste Richardson (1 out of 4 patents)

15 patents: Sort by Forward Citations

1. 12480109 - Compositions and methods for kallikrein (KLKB1) gene editing (2025-11-25),

2. 12460205 - Compositions and methods for treating alpha-1 antitrypsin deficiency (2025-11-04),

3. 12391722 - Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) (2025-08-19),

4. 12214023 - Compositions and methods for expressing factor IX (2025-02-04),

5. 12173284 - Modified guide RNAs (2024-12-24),

6. 12077483 - Modified amine lipids (2024-09-03),

7. 12037583 - Compositions and methods for immunooncology (2024-07-16),

8. 11965165 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2024-04-23),

9. 11851659 - Compositions and methods for immunooncology (2023-12-26),

10. 11795460 - Compositions and methods for TTR gene editing and treating ATTR amyloidosis (2023-10-24),

11. 11697806 - Polynucleotides, compositions, and methods for genome editing (2023-07-11),

12. 11673911 - Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) (2023-06-13),

13. 11549107 - Compositions and methods for treating alpha-1 antitrypsin deficiency (2023-01-10),

14. 11479767 - Modified guide RNAs (2022-10-25),

15. 11466271 - Compositions and methods for the treatment of hemoglobinopathies (2022-10-11),

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. The company's goal is to harness the power of CRISPR to create long-lasting treatments for severe genetic diseases. Intellia's innovative approach has the potential to revolutionize the field of medicine and improve the lives of patients around the world.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

15 Patents

#145 in

#20,400 in

#38,669 in the World

Cambridge, MA, United States of America

Intellia Therapeutics, Inc.

Forward Citations = 10

41 inventors:

Walter R Strapps (6 out of 19 patents)

Shobu Odate (5 out of 5 patents)

Reynald Michael Lescarbeau (5 out of 5 patents)

4. Yi Yang (3 out of 4 patents)

5. Amy Madison Rhoden Smith (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…